Introduction
COVID-19 associated mucormycosis (CAM) is the result of the severe
immunosuppression caused by COVID-19 and its
management1. The first series of CAM was published in
February 20212, since then there is an upsurge of
these cases. The target group for CAM includes patients with a history
of COVID-19, corticosteroid therapy, and uncontrolled blood sugars.
These patients with alarming signs and symptoms should be considered for
comprehensive evaluation3. The nasal cavity is the
first point of contact and the fungus harboring the nasal cavity makes
DNE an important tool of diagnosis. But changing trends and varied
presentation of the disease in this epidemic include patients with
minimal signs instead of established red flag symptoms. DNE in such
cases is normal. The early stages of CAM need not have necrosis,
discoloration, or blackening in the nasal cavity (Figure 1-a,b,c,d). The
limitation of endoscopy is in evaluation of the disease beyond the
confinements of the nasal cavity. Then comes the role of imaging and
biopsy in making an early and accurate diagnosis4.
This study was designed to determine the sensitivity and diagnostic
accuracy of endoscopy and imaging in comparison to potassium hydroxide
calcofluor white mount KOH mount and correlating them. This will help to
formulate an ideal diagnostic strategy in suspected cases of invasive
fungal sinusitis.